Health ❯ Healthcare ❯ Adverse Effects

Drug Safety

Clinical Safety Profiles Ketamine Side Effects Skin Reactions TUKYSA Safety Profile Cytokine Release Syndrome Heart Failure Risks Apitegromab Side Effects

FDA Approves Isembyld, First Muscle‑Directed Therapy for Spinal Muscular Atrophy

Isembyld is an IV add‑on to existing SMN2 treatments that showed motor improvement in children and will begin U.S. shipments.

Aficamten Improves Symptoms and Exercise Capacity in Nonobstructive HCM

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

Padcev–Keytruda Cuts Recurrence and Death Risk in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer